Status:
COMPLETED
Collection and Banking of Leukemia Cells MDS/AML
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Brigham and Women's Hospital
National Institutes of Health (NIH)
Conditions:
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this research study is to determine if it is feasible to collect leukemia cells from patients ahead of time (before they undergo further treatments) so that these cells (after being radiat...
Detailed Description
* Leukemia cells will be collected by one or more of the following methods: 1)Routine blood draw 2)Bone marrow aspirate 3) Leukapheresis. The physician and study staff will determine which of the meth...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with AML will be eligible for banking at the time of relapse or primary induction failure or at the time of AML diagnosis they are 60 years of age or older, AML arising out of background MDS or MPD or AML known with high risk cytogenetics
- Patients with MDS-RAEB-1 or RAEB-II, CMML-1 or CMML-II
- Patients must have \>5% blast in bone marrow or peripheral blood
- ECOG Performance Status 0-2
- Age greater than or equal to 18 years
- Reasonable likelihood, in the physician's opinion, that the patient will be a candidate for allogeneic stem cell transplant
Exclusion
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00809367
Start Date
October 1 2008
End Date
May 1 2011
Last Update
February 7 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115